Administering surfactant during pediatric extracorporeal membrane oxygenation (ECMO) may influence important clinical variables but has been insufficiently described. Ninety-six courses of ECMO from our center were retrospectively assessed, and 89 surfactant doses were identified during 37 ECMO courses. Surfactant administration was associated with a respiratory indication for ECMO and increased durations of ECMO and positive pressure ventilation. Hospital survival was 64.9% (24) in surfactant-treated ECMO courses and 72.9% (43) otherwise (p = 0.41). Dynamic compliance of the respiratory system (C dyn ; shown as least squares mean [standard error] in ml/cm H 2 O/kg by mixed-effects modeling) increased significantly from 0.34 (0.03) before surfactant to 0.40 (0.03) within 12 hours (p = 0.023) and to 0.45 (0.03) within 24 hours (p < 0.001) of surfactant administration. Other mechanical ventilator parameters, ECMO settings, and arterial blood gas results did not differ significantly after surfactant administration. Among surfactant recipients, significantly increased C dyn was observed in the nonsurgical group (n = 20) but not in the cardiac surgery group (n = 17). In conclusion, respiratory system compliance is increased after surfactant administration and noncardiac surgical patients may preferentially benefit from this therapy. Surfactant administration was associated with longer durations of mechanical support, but not with unfavorable mortality. ASAIO Journal 2015; 61:682-687.
also associated with increased rates of adverse events, with 95% of children who survive ≥21 days of ECMO having at least one complication. 5, 8 Therefore, interventions aimed at decreasing ECMO duration may improve patient outcomes. Successful ECMO decannulation necessitates sufficient improvement in cardiac and/or respiratory function. Underlying causes of organ dysfunction must be addressed, and organ function may also be supported pharmacologically or mechanically. Innovative, aggressive organ support strategies may hasten ECMO decannulation and further improve patient outcome. Administering pulmonary surfactant during ECMO may be such a therapy.
Surfactant is a naturally occurring lipoprotein that decreases alveolar surface tension, which reduces atelectasis and improves lung compliance. Surfactant abnormalities have been described in neonates on ECMO and in many pediatric conditions that may require ECMO, including pneumonia, the acute respiratory distress syndrome (ARDS), and convalescence from cardiopulmonary bypass (CPB) surgery. [9] [10] [11] [12] [13] Surfactant administration often improves oxygenation and may improve survival in children with respiratory failure not on ECMO, although data are heterogeneous and do not support routine use. [14] [15] [16] [17] Administration of surfactant has been shown to decrease duration of neonatal ECMO in a single study from 1993. 18 However, there are scant data describing the administration of surfactant during pediatric ECMO outside the neonatal period. 19 To that end, we retrospectively reviewed surfactant administration during pediatric ECMO at our institution, including pertinent outcome variables such as respiratory system compliance, ECMO duration, and patient survival. This article describes 96 courses of ECMO and 89 doses of surfactant administered during 37 of those courses.
Materials and Methods
This study was approved by the Institutional Review Boards of the Children's Hospital of Pittsburgh (CHP) of University of Pittsburgh Medical Center and of Rainbow Babies and Children's Hospital (University Hospitals of Cleveland). Patients treated with ECMO in the pediatric intensive care unit (ICU) or cardiac ICU at CHP between January 2010 and March 2013 were included in the study. Multiple courses of ECMO for the same child were considered as separate events. Exclusion criteria were patient aged 18 years or older and initiation or termination of ECMO at another center. Data were retrospectively extracted from the electronic health record and from an institutional ECMO database for each course of ECMO, including demographics, performance of cardiac surgery during the hospitalization, type of cannulation (venovenous or venoarterial), and primary indication for ECMO, dichotomized as "respiratory failure" or "cardiac failure" (including extracorporeal cardiopulmonary resuscitation, which is ECMO as an extension of cardiopulmonary resuscitation).
All patient care, including all aspects of surfactant prescription (indication, dose, delivery technique, timing, etc.), was at the discretion of the clinical team. The dose and timing of all surfactant administrations during ECMO were collected. Arterial blood gas (ABg) results, mechanical ventilator parameters, and ECMO settings within one calendar day of any surfactant administration were extracted for patients treated with surfactant. Median values of these variables were calculated for the 6 hours before (baseline) surfactant administration and for three epochs after surfactant administration: 0-6 hours, 0-12 hours, and 0-24 hours. Dynamic compliance of the respiratory system (C dyn ) was calculated using exhaled tidal volume (Tv), peak inspiratory pressure (PIP), and positive end-expiratory pressure (PEEP) using the equation: C dyn = Tv/(PIP − PEEP). Maximum C dyn was calculated for the 6 hours before surfactant administration (baseline) and for the three epochs described earlier. The end of positive pressure ventilation (PPv) was defined as the onset of 24 hours without invasive or noninvasive PPv.
All analyses were performed using SAS version 9.3 (SAS Inc., nC). Patient demographics, clinical characteristics, and outcome variables were compared between groups using Wilcoxon two-sample test for continuous variables and χ 2 or fisher's exact test for categorical variables. Overall changes from baseline to each aforementioned epoch in ECMO settings, ABg results, and ventilator parameters were explored using mixed-effects models. Because surfactant prescription was not standardized (i.e., dosing, brand, indications), we treated administration as a random factor in the analysis. Patients were divided based on the performance or absence of cardiac surgery during the hospitalization. Mixed-effects modeling was used to compare C dyn between these groups at baseline, in the 0-24 hour epoch and as absolute change from baseline to 0-24 hours, and analysis was adjusted for factors that differed significantly between groups. All p values presented are two sided, and p < 0.05 is considered as statistically significant. variables are presented as least squares mean (standard error), n (%), or median (interquartile range) unless otherwise noted. Table 1) . Most patients were less than 12 months old, and approximately half underwent cardiac surgery during their hospital stay (n = 49). The recorded indication for ECMO was respiratory support in 26 courses (27.1%), mostly secondary to ARDS or respiratory tract infection (21 courses). venoarterial cannulation was used 88 times (91.7%), and median duration of ECMO was 69 (28.5-129) [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] days, p = 0.004) in treated patients, there was no significant decrease in survival to hospital discharge associated with surfactant administration (64.9 vs. 72.9%, p = 0.41).
Results

ninety-six courses of ECMO met study criteria (
ECMO parameters and ABg results did not differ significantly after surfactant administration ( Table 2) Table 3 ). Dynamic compliance of the respiratory system increased after surfactant administration in both surgical and nonsurgical patients (Figure 2 ), but only reached statistical significance in the noncardiac surgery Among the entire study population, survival to hospital discharge did not differ between cardiac surgery and noncardiac surgery patients (75.5 vs. 63.8%, p = 0.306). Surfactant administration was associated with decreased survival in cardiac surgery patients (52.9 vs. 87.5%, p = 0.013) but not in nonsurgical patients (75.0 vs. 55.6%, p = 0.226; Table 3 ). In the nonsurgical group, surfactant administration was associated with younger age; lower weight; a respiratory ECMO indication; and longer durations of ECMO, PPv, ICU care, and hospitalization. There were no associations between surfactant use and available patient characteristics in the surgical cohort.
Twenty-seven children were treated with multiple doses of surfactant. There were no significant differences in demographics or outcomes versus the 10 children treated with a single dose ( Table 4 ). After controlling for both surfactant type and number of doses, we again found a significant increase in C dyn that was unique to the noncardiac surgery group (p = 0.008) and not observed in the cardiac surgery group (p = 0.654).
Discussion
This single-center, retrospective description of our recent pediatric ECMO experience supports that surfactant administration is associated with improved respiratory system compliance and may impact patient outcome. To our knowledge, this is the largest published cohort of pediatric patients given surfactant during ECMO. Among 37 courses of ECMO in which 89 doses of surfactant were administered, our data demonstrate that C dyn increased significantly from 0.340 to 0.450 ml/ cm H 2 O/kg (p < 0.001). This 32% increase in compliance is less than the 76.1% increase after surfactant reported by Hermon et al. 19 Our findings are derived from a larger population and multiple measurements of C dyn per epoch, as opposed to three singular measurements (baseline, 4 hours, and 10 hours) of C dyn per patient. Both studies support that surfactant may increase C dyn , which may in turn improve outcome. An increased C dyn often precedes successful ECMO discontinuation and is associated with improved survival in children on ECMO not treated with exogenous surfactant. 20 A prospective study could test whether the surfactant-induced increases in C dyn seen in our cohort improve patient outcome.
In our cohort, ABg results, ECMO parameters, and mechanical ventilator settings (other than increased tidal volume and C dyn ) were similar before and after surfactant, suggesting that patients tolerated surfactant administration well. Complications of surfactant include transient bradycardia and/or desaturation because of airway obstruction and vagal stimulation by the viscous material, and also pneumothorax, pulmonary hemorrhage, and hypotension. [14] [15] [16] 21, 22 Desaturation/bradycardia events may have occurred in our cohort but not be reflected in our analysis because of their transient nature or may have been mitigated by sufficient oxygen delivery from the ECMO system. Transient airway obstruction was likely in our cohort as evidenced by the lack of increase in C dyn observed within 6 hours of surfactant, although the typical practice of limiting endotracheal tube suctioning acutely after surfactant administration may also have influenced this finding. Overall, although our study was not designed to thoroughly evaluate the safety of administering surfactant to children on ECMO, our data suggest that this practice was well tolerated by patients. further safety data are needed, especially in patients supported by venovenous ECMO, who compromised a very small part of our treated cohort (n = 2) and in whom adverse effects of surfactant may be more prevalent and severe.
The biological plausibility of surfactant administration improving C dyn is based on these children having insufficient surfactant quantity and/or function. Previous literature has reported surfactant abnormalities in children after CPB and in children with ARDS or acute respiratory infections, which were the diagnoses in most of our subjects. 9,10,13 Similar to CPB, the ECMO circuit Values for the 6 hr before and the 24 hr after administration calculated using mixed-effects modeling and reported as least squares mean ± standard error.
ABG, arterial blood gas; PIP, peak inspiratory pressure; PEEP, positive end-expiratory pressure; TV, exhaled tidal volume. may elicit a systemic inflammatory response that alters surfactant, and abnormal surfactant composition has been reported in neonates on ECMO. 11, 12, 23 Thus, even those children in our cohort with conditions not typically associated with surfactant dysfunction (e.g., cardiac arrest) may have had some degree of surfactant abnormality secondary to ECMO itself. Surfactant prescription was likely influenced by understanding of these risks of surfactant insufficiency, but patient-level factors of respiratory dysfunction, such as abnormal lung mechanics or radiographic findings, likely also impacted the decision to treat with surfactant. In addition, some practitioners may avoid surfactant use when lung disease is related to inflammation and edema, such as in ARDS.
In subgroup analysis, surfactant administration was not associated with significant improvements in C dyn among cardiac surgery patients. Dynamic compliance of the respiratory system did increase by approximately 15% from 0.423 to 0.486 ml/cm H 2 O/kg (p = 0.177) after surfactant in this group, so our study may have been simply underpowered for this analysis. Alternatively, the higher baseline C dyn in our cardiac surgery patients (vs. nonsurgical patients) suggests that surfactant function in this subgroup may have been sufficient as to render exogenous treatment ineffective. Although several authors have previously described abnormalities in surfactant composition after CPB, some previous evidence shows that surface tension is maintained despite abnormal surfactant composition. 9, 24 Identification of C dyn thresholds or other patient-level factors associated with surfactant efficacy could improve clinical care for surgical and nonsurgical patients, because only select patients are likely to benefit from therapy.
The overall survival of our ECMO cohort (69.8%) compares favorably with previous reports, in which overall pediatric ECMO survival is often approximately 50%. [2] [3] [4] Surfactant administration was associated with increased durations of PPv and ECMO, but no change in survival in our observational study. One could interpret this to support surfactant administration (it mitigated worsened mortality in the "sicker" patients who received it) or refute it (it prolonged mechanical support and did not improve survival), but only a controlled, prospective study can determine the effects of surfactant administration on ECMO outcomes.
Survival in our cardiac surgery subgroup was 75.6%. This also compares favorably with previous reports of children treated with ECMO after cardiac surgery. [25] [26] [27] [28] This likely reflects advances that we have made as an international ECMO community, although institution-specific practices may contribute as well. 29, 30 Surprisingly, there was a significant association between surfactant administration and unfavorable mortality in cardiac surgery patients (52.9 vs. 87.5%, p = 0.013). This may reflect preferential administration to more severely ill patients, premature ECMO discontinuation after transiently increased C dyn , or inflammatory modulation by exogenous surfactant protein B. 31 In the nonsurgical cohort, associations between surfactant administration and increased durations of ECMO, PPv, and ICU care could be interpreted that surfactant was administered to sicker patients and perhaps had a positive influence on survival. Prospective study of the impact of surfactant on ECMO survival is needed.
Our study has several limitations beyond those previously mentioned. Although this is the largest reported cohort of children on ECMO treated with surfactant, it is still a limited sample size from a single institution. The administration of surfactant was not standardized in regards to indication, dose, formulation, or delivery technique. Surfactant may have been administered based on patient-level variables not included in our database. granular details about the drug administration, such as patient positioning and the number of aliquots used, are not available. Surfactant quantity and function were not measured before exogenous administration. Imprecision in C dyn measurements was minimized by measuring pressure and volume at the endotracheal tube (not the ventilator) and by using median values (as opposed to individual values) and mixed-effect models. Moreover, increased C dyn is not necessarily equivalent to improved lung function, which is difficult to ascertain during ECMO support. Atrial decompression during ECMO may influence pulmonary mechanics, but data pertaining to its use were not available in the data set. Surfactant is costly to administer, which should influence its prescription; however, financial data were not included in our database. Most importantly, like all retrospective clinical studies, we are only able to show association not causation. Any conclusion about effects on survival from our study should be interpreted cautiously, because of the observational study design, the large number of cofounding variables, and the absence of illness-severity variables from our data (e.g., PRISM, RACHS-1).
Conclusions
In conclusion, in the largest reported cohort of surfactant administration during pediatric ECMO, surfactant treatment was associated with a significant improvement in respiratory system compliance. further study is needed to better inform clinicians regarding which patient-level variables are associated with improved C dyn and the effects of surfactant administration on ECMO outcome. Variables are compared between children treated with multiple doses of surfactant during ECMO vs. those treated with a single dose using Fisher's exact or Wilcoxon rank-sum test. Data are represented as median (interquartile range) or n (%). eCPR, extracorporeal cardiopulmonary resuscitation; ICU, intensive care unit; PPV, positive pressure ventilation.
